Abstract: An antitumor effect enhancer for enhancing the antitumor effects of an antitumor substance, which comprises a compound represented by the following formula (1): wherein each R independently represents a hydrogen atom, a lower alkyl group, an aryl group, an allyl group, an aralkyl group, a halogen atom, a hydroxyl group, an amino group, R?O—, R?(C?O)—, R?(C?O)O—, or R?O(C?O)—, wherein R? is an alkyl group containing 1 to 5 carbon atoms, or a pharmaceutically acceptable salt thereof.

Abstract: An antitumor effect enhancer for enhancing the antitumor effects of an antitumor substance, which comprises a compound represented by the following formula (1): wherein each R independently represents a hydrogen atom, a lower alkyl group, an aryl group, an allyl group, an aralkyl group, a halogen atom, a hydroxyl group, an amino group, R?O—, R?(C?O)—, R?(C?O)O—, or R?O(C?O)—, wherein R? is an alkyl group containing 1 to 5 carbon atoms, or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a method of treating a warm-blooded animal, especially a human, having a proliferative disease comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one telomerase inhibitor, to a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease and finally to the use of at least one telomerase inhibitor for the preparation of a medicament for the delay of progression or treatment of Imatinib-resistant leukemia.

Abstract: A method of treating BCR-ABL positive leukemia in a warm-blooded animal comprising administering the combination of N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and telomestatin is disclosed. The combination may optionally have a pharmaceutically acceptable carrier, and the compounds may be administered for simultaneous, separate or sequential use.

Abstract: The invention relates to a method of treating a warm-blooded animal, especially a human, having a proliferative disease comprising administering to the animal a combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one telomerase inhibitor, to a combination comprising (a) and (b) as defined above and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the delay of progression or treatment of a proliferative disease and finally to the use of at least one telomerase inhibitor for the preparation of a medicament for the delay of progression or treatment of Imatinib-resistant leukemia.